Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis.

Journal Article (Journal Article)

In a pooled population analysis, we investigated the pharmacokinetics of i.v. anidulafungin in four studies across a full range of adult and pediatric ages in patients with confirmed, suspected, or at high risk of invasive candidiasis (IC). Relationships between anidulafungin exposure and key efficacy end points (global response of success and all-cause mortality) and safety end points (all-cause hepatic or gastrointestinal adverse events) in all patients and separately in pediatric patients and the appropriate dosing regimen for IC treatment in pediatric patients were evaluated. Pediatric patients received a 3.0 mg/kg (maximum 200 mg) i.v. loading dose and 1.5 mg/kg (maximum 100 mg) daily thereafter. Adults received a 200 mg i.v. loading dose and 100 mg daily thereafter. Estimated systemic anidulafungin exposures were similar across age groups (neonates to adults) at the weight-based doses studied in pediatric patients. No clear associations were identified between anidulafungin exposure and efficacy or safety end points.

Full Text

Duke Authors

Cited Authors

  • Xie, R; McFadyen, L; Raber, S; Swanson, R; Tawadrous, M; Leister-Tebbe, H; Cohen-Wolkowiez, M; Benjamin, DK; Liu, P

Published Date

  • August 2020

Published In

Volume / Issue

  • 108 / 2

Start / End Page

  • 316 - 325

PubMed ID

  • 32189334

Pubmed Central ID

  • PMC7485140

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1002/cpt.1831


  • eng

Conference Location

  • United States